Watch NMRA. Know when insiders buy.
One email the day a filing lands. Free.
Work order
38
FLAG · insiders 38, shorts 38
Insiders, 90 days
−$270K
net selling · 0 buys, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $246.1MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$212.7MNET CASH $63.9M52W 0.92 – 3.59NEXT EARNINGS Nov 5 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$42.2M | −$43.1M | — | -0.23 | −$39.5M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$52.9M | −$53.5M | — | -0.30 | −$46.4M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$58.5M | −$59.5M | — | -0.35 | −$48M | — | — | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$57.7M | −$56.8M | — | -0.35 | −$46.6M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$54M | −$52.7M | — | -0.33 | −$52.4M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$70.9M | −$68M | — | -0.42 | −$59.4M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$62.9M | −$58.8M | — | -0.37 | −$50.3M | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$76.6M | −$72.5M | — | -0.45 | −$33.5M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$63.8M | −$58.7M | — | -0.37 | −$56.2M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$60.1M | −$53.7M | — | -0.34 | −$43M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$114M | −$108.7M | — | -0.04 | −$51.4M | $44K | −$51.5M | Mar 3 |
| Q3 2023 · Sep 30 | — | — | — | −$56.9M | −$53M | — | -1.14 | −$47.8M | $37K | −$47.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$241.2M | −$236.9M | — | -1.45 | −$206.4M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$263.5M | −$243.8M | — | -1.53 | −$182.9M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$252.1M | −$235.9M | — | -3.63 | −$163.3M | $117K | −$163.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$135.9M | −$130.9M | — | -4.81 | −$114.9M | $511K | −$115.4M | — | — |
Every number comes from Neumora Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.